Flow Cytometry Markers for Myeloid Cell Identification: A Practical Guide

Flow cytometry markers for myeloid cell identification are the cornerstone of modern immunophenotyping, enabling researchers to resolve the extraordinary heterogeneity of myeloid populations in blood, bone marrow, spleen, lymph nodes, and tumor microenvironments with single-cell precision. As the innate immune arm most directly implicated in inflammation, pathogen clearance, and tumor immune evasion, myeloid cells demand a rigorous and carefully designed panel strategy — and flow cytometry remains the gold standard for delivering it.

The Myeloid Lineage: A Brief Overview

All myeloid cells arise from hematopoietic stem cells (HSCs) in the bone marrow through a hierarchy of increasingly restricted progenitors. The granulocyte-monocyte progenitor (GMP) gives rise to neutrophils, eosinophils, basophils, and monocytes, while the monocyte-dendritic cell progenitor (MDP) branches further into common dendritic cell progenitors (CDPs) that seed both conventional and plasmacytoid dendritic cell lineages. Understanding this ontogeny is essential for interpreting flow cytometry data, because progenitor-stage markers (e.g., CD34, CD117/c-Kit) overlap substantially with mature subset markers.

Monocytes in human peripheral blood are classified into three functional subsets by their co-expression of CD14 (LPS co-receptor) and CD16 (FcγRIII):

• Classical monocytes (CD14⁺⁺CD16⁻): ~85% of circulating monocytes; dominant phagocytic and inflammatory effectors.
• Intermediate monocytes (CD14⁺CD16⁺): ~5%; elevated in sepsis, HIV, and cardiovascular disease.
• Non-classical monocytes (CD14⁺CD16⁺⁺): ~10%; patrol the vascular endothelium and are major producers of TNF and IL-1β upon TLR7/8 stimulation.

Macrophages represent the tissue-resident and monocyte-derived phagocytes. They polarize along a spectrum from pro-inflammatory (classically activated; historically "M1": CD86⁺HLA-DR^hi) to anti-inflammatory and tissue-repair (alternatively activated; historically "M2": CD163⁺CD206⁺MerTK⁺). Tissue-resident macrophages express CX3CR1, Tim4, and (in mice) F4/80 (ADGRE1), markers that distinguish them from monocyte-derived infiltrators.

Dendritic cells (DCs) comprise three major subtypes in humans: conventional DC1 (cDC1: CLEC9A⁺/DNGR-1⁺, XCR1⁺), specialized for cross-presentation; conventional DC2 (cDC2: CD11c⁺CD1c/BDCA1⁺CD11b⁺); and plasmacytoid DCs (pDC: CD123⁺BDCA2/CD303⁺BDCA4⁺). Key pan-myeloid markers — CD11b (integrin αM, ITGAM), CD33 (Siglec-3, pan-myeloid), and HLA-DR (MHC class II, encoded by HLA-DRA/HLA-DRB loci) — anchor virtually every myeloid panel and enable clear discrimination from lymphoid and erythroid populations. Lineage markers including CD3 (T cells), CD19 (B cells), CD56 (NK cells), and CD235a (erythrocytes) serve as dump-channel exclusions.

Flow Cytometry Marker Panels for Myeloid Cell Identification

Panel design for myeloid immunophenotyping requires balancing marker brightness, spectral overlap, and antigen density. A minimum 6-color panel is sufficient for basic human PBMC analysis; 10–20 color panels are standard for comprehensive subset resolution. The table below summarizes key positive and exclusion markers for the principal human myeloid subsets.

Table 1. Human and mouse myeloid cell identification by flow cytometry — key surface markers for each subset. Human macrophages are identified using CD64 and MerTK, not F4/80 (ADGRE1), which is mouse-specific. Dendritic cell subsets are resolved with CLEC9A (cDC1) and CD1c/BDCA1 (cDC2). Adapted from Guilliams et al., Nat Rev Immunol 2014.

Important species note: F4/80 (ADGRE1) is the canonical mouse macrophage marker but is absent on human macrophages. For human tissue macrophage identification, use CD64 (FcγRI) in combination with MerTK — this combination reliably discriminates tissue-resident macrophages from monocytes and DCs in samples such as bronchoalveolar lavage, tumor digests, and gut lamina propria. This distinction is critical when translating mouse panel designs to human studies.

Pan-myeloid lineage markers that anchor every panel include CD11b (ITGAM) for broad myeloid coverage, CD33 (Siglec-3) for pan-myeloid exclusion of lymphocytes, and HLA-DR as a myeloid activation and maturation marker (encoded by the HLA-DRA and HLA-DRB loci). These are supported by peer-reviewed subset characterization studies including the landmark Ginhoux and Guilliams review of myeloid cell heterogeneity (Ginhoux & Guilliams, Immunity 2016).

Flow Cytometry Applications in Myeloid Tissue Research

Flow cytometry myeloid panel design varies substantially depending on the tissue and the biological question.

Tumor microenvironment (TME). Tumor-associated macrophages (TAMs) are among the most abundant non-cancerous cells in solid tumors and represent a major immunosuppressive axis. Flow cytometry distinguishes M1-like TAMs (CD86⁺HLA-DR^hiCD163⁻) from M2-like TAMs (CD163⁺CD206⁺CD64⁺MerTK⁺). More recently, the TREM2⁺ macrophage subset was identified as a dominant immunosuppressive population in multiple human tumor types by high-dimensional single-cell RNA-seq and confirmed by flow cytometry (Zilionis et al., Immunity 2019). Myeloid-derived suppressor cells (MDSCs) — monocytic MDSCs (M-MDSC: HLA-DR^lowCD14⁺CD15⁻) and polymorphonuclear MDSCs (PMN-MDSC: CD15⁺CD11b⁺HLA-DR⁻) — are increasingly included in TME panels as therapeutic targets.

Bone marrow analysis. In acute myeloid leukemia (AML), flow cytometry immunophenotyping is the standard method for blast identification and minimal residual disease (MRD) monitoring. A core AML panel includes: CD45 (for blast gating by dim CD45/low side-scatter), CD34 (HSC/progenitor), CD117/c-Kit, CD33, CD13, HLA-DR, and myeloperoxidase (MPO, intracellular). Aberrant antigen co-expression — such as CD7 on myeloid blasts or CD56 on monocytic AML — defines the leukemia-associated immunophenotype (LAIP) used for MRD tracking.

Spleen and lymph node. Splenic macrophages are anatomically segregated: red pulp macrophages (F4/80^hiCD11b^low in mice) clear senescent red blood cells; marginal zone macrophages (SIGN-R1⁺ in mice, SIGLEC1⁺ in humans) capture blood-borne antigens. Standard splenic myeloid panels use CD11b, F4/80, Ly6C, and Ly6G (mouse) or CD14, CD16, and HLA-DR (human).

Gut and lung. Intestinal tissue-resident macrophages are distinguished by CX3CR1⁺Tim4⁺MHC II⁺ expression; monocyte-derived infiltrating macrophages are CX3CR1^lowTim4⁻. In the lung, alveolar macrophages are characterized by SiglecF⁺CD11c⁺ (mouse) or CD169⁺CD11b⁻ (human).

Technical Considerations for Myeloid Flow Cytometry

Myeloid cells present several unique technical challenges that require deliberate experimental design.

Fc receptor (FcγR) blocking. This is the single most important pre-staining step for myeloid panels. Monocytes, macrophages, dendritic cells, and neutrophils express high levels of FcγRI (CD64), FcγRII (CD32), and FcγRIII (CD16), which bind the Fc region of antibodies non-specifically — producing false-positive signal across all channels. Always incubate cells with a dedicated FcR blocking reagent (e.g., Human TruStain FcX, BD Fc Block) for 10 minutes at 4°C before adding any antibody cocktail. For mouse samples, use anti-mouse CD16/32 (clone 93 or 2.4G2).

Live/dead discrimination. Myeloid cells, particularly from tissue digests, have higher basal rates of cell death than lymphocytes. Viability dyes — DAPI or 7-AAD (incompatible with fixation) for unfixed samples, or amine-reactive dyes (LIVE/DEAD Fixable, Zombie Aqua/NIR) for fixed samples — are mandatory. Dead cells bind antibodies non-specifically and will contaminate every gate.

Autofluorescence. Myeloid cells, especially macrophages and monocytes, have intrinsically high autofluorescence in the FITC (530/30) and PE (585/42) channels due to flavins, NAD(P)H, and other endogenous fluorophores. This can mask dim markers. Strategies to mitigate this include: (1) using brighter tandem dyes (PE-Cy7, BV785) for dim markers on myeloid cells; (2) applying spectral unmixing with autofluorescence as a defined reference spectrum; (3) using dump channels to gate out highly autofluorescent dead cells and debris.

Fixation. For biosafety (e.g., HIV-infected primary cells, tumor biopsies) or intracellular targets (cytokines, transcription factors, MPO), paraformaldehyde (PFA, 1–4%) is the standard fixative. Intracellular cytokine staining (ICS) requires permeabilization with saponin-based or methanol-based buffers after fixation. Note that FcγR blocking should be performed before fixation, as fixation can cross-link receptors and reduce blocking efficiency.

Compensation controls. Single-color compensation controls are required for every fluorochrome in the panel, using the same bead or cell type that will be used in the experiment. Anti-mouse Ig capture beads work for most antibody-based controls; for tandem dyes, use biological cells rather than beads to accurately capture spectral emission variability.

Tissue dissociation. Solid tissue myeloid panels require single-cell suspension preparation. Enzymatic digestion (collagenase IV, DNase I) is preferred for maximizing cell recovery, but some surface markers — notably CD11b, F4/80, and CD64 — are sensitive to protease digestion. Titrate enzyme concentrations and incubation times empirically, and include a digestion-only staining control to detect marker loss.

BioHippo Myeloid Research Reagents

BioHippo stocks a comprehensive range of primary antibodies and myeloid cell models for flow cytometry and immunophenotyping research.

Flow cytometry antibodies for myeloid markers:

• Anti-Mouse CD11b/ITGAM Antibody (DC13), PerCP — validated for mouse myeloid panel flow cytometry
• Anti-CD11b/ITGAM Polyclonal Antibody — human/rabbit, ELISA, WB, IHC
• Anti-Human CD33 Antibody (P67.6), PerCP — pan-myeloid marker for human flow cytometry
• Anti-Human CD33 Antibody (M195), PerCP — therapeutic clone for AML immunophenotyping
• Anti-Human HLA-DRA/DRB4 Antibody (GPC-8-9) — validated for flow cytometry and ELISA
• Anti-Human HLA-DRA/DRB4 Antibody (GPC-8-6-45) — HLA-DR for myeloid activation panels
• CD16 Antibody (NSJ Bioreagents) — monocyte subset discrimination (CD14/CD16 co-staining)
• Anti-EMR1/ADGRE1 (F4/80)-FITC Antibody (Alomone Labs) — mouse macrophage marker, FITC-conjugated for flow
• PE/Cyanine5.5 Anti-Mouse F4/80 Antibody [CI:A3-1] — bright tandem for mouse macrophage panels
• Anti-Human CD13/ANPEP Nanobody (SAA1324) — myeloid promyelocyte/AML marker

Myeloid cell models:

• THP-1 cells (Cytion) — human monocytic leukemia line; differentiates into macrophage-like cells with PMA; validated for flow cytometry and immunophenotyping
• Mouse Bone Marrow-Derived Macrophages (mBMDM) — primary macrophage model for polarization and TME studies
• HL-60 cells (Cytion) — human acute promyelocytic leukemia line; differentiates into neutrophil- or monocyte-like cells; used for myeloid differentiation and AML research
• HMC3 cells (Cytion) — human microglial cell line; CNS-resident myeloid model for neuroinflammation research

Frequently Asked Questions

What markers identify myeloid cells by flow cytometry?

The most reliable pan-myeloid markers for flow cytometry are CD11b (ITGAM), CD33 (Siglec-3), and HLA-DR. CD11b is expressed broadly across monocytes, macrophages, granulocytes, and conventional dendritic cells in both humans and mice. CD33 is expressed on all mature myeloid cells and their progenitors (except neutrophils at lower levels) and is negative on most lymphocytes. HLA-DR (encoded by HLA-DRA/HLA-DRB) marks antigen-presenting myeloid cells including monocytes, macrophages, and dendritic cells, but is low or absent on neutrophils and granulocyte precursors. Together, a CD11b/CD33/HLA-DR combination allows initial myeloid gate establishment before sub-gating into individual subsets with lineage-specific markers.

How do you identify macrophages by flow cytometry?

Human macrophages in tissue samples are best identified by co-expression of CD64 (FcγRI) and MerTK, which together distinguish them from monocytes (CD64^lowMerTK⁻) and dendritic cells. Additional markers include CD11b⁺, HLA-DR⁺, and high forward scatter (large cell size). For polarization state, add CD86 and HLA-DR (M1-like activation) or CD163 and CD206 (M2-like, scavenger/anti-inflammatory). In mouse tissue, F4/80 (ADGRE1) is the gold standard macrophage marker — it is not expressed on human cells. F4/80 combined with CD11b, Ly6C, and MHC II defines mouse macrophage subsets across tissues.

What is the difference between monocytes and macrophages?

Monocytes are circulating bone marrow-derived cells that patrol the blood and respond rapidly to infection or tissue damage. Macrophages are tissue-resident or monocyte-derived cells that have extravasated and differentiated within a tissue niche. Phenotypically, monocytes are CD14⁺CD16^±CD64^lowMerTK⁻CCR2⁺, while macrophages are CD64^hiMerTK⁺CCR2⁻ and express tissue-specific markers (e.g., Tim4 in peritoneum, SiglecF in lung, TREM2 in brain microglia). Functionally, macrophages are longer-lived, self-renewing in some tissues, and adopt specialized effector programs shaped by local cytokine environments.

What is a myeloid cell?

A myeloid cell is any blood cell that derives from the myeloid lineage of hematopoiesis — the developmental branch originating from HSCs through the common myeloid progenitor (CMP). The myeloid lineage produces monocytes, macrophages, dendritic cells, neutrophils, eosinophils, basophils, mast cells, erythrocytes, and platelets (megakaryocytes). In immunology, "myeloid cells" typically refers to the innate immune myeloid compartment: monocytes, macrophages, dendritic cells, and granulocytes. These cells express characteristic markers including CD11b, CD33, and CD13, and are the primary mediators of innate immune recognition, phagocytosis, and antigen presentation.

What are the main myeloid cell types in the tumor microenvironment?

The tumor microenvironment (TME) contains a diverse and dynamic myeloid compartment. The dominant populations are tumor-associated macrophages (TAMs), which comprise M1-like (pro-inflammatory: CD86⁺HLA-DR^hi) and M2-like (immunosuppressive: CD163⁺CD206⁺TREM2⁺) subsets. Tumor-infiltrating monocytes (CD14⁺HLA-DR^low) can differentiate into TAMs locally. Myeloid-derived suppressor cells (MDSCs) — both monocytic (M-MDSC: CD14⁺HLA-DR^low) and polymorphonuclear (PMN-MDSC: CD15⁺CD11b⁺) subtypes — suppress T cell responses and promote tumor immune evasion. Tumor-infiltrating dendritic cells, including cDC1 (CLEC9A⁺) specialized for cross-presentation of tumor antigens to CD8⁺ T cells, are also major functional components of anti-tumor immunity (Zilionis et al., Immunity 2019).

Why do myeloid cells require FcR blocking before flow cytometry staining?

Myeloid cells express high levels of Fc gamma receptors — FcγRI (CD64), FcγRII (CD32), and FcγRIII (CD16) — on their surface. These receptors bind the Fc (constant) region of immunoglobulin G antibodies with high affinity, which means that any fluorochrome-conjugated antibody added to an unstained sample will bind non-specifically to myeloid cells via its Fc tail, not its antigen-specific Fab domain. The result is false-positive staining in every channel, making all downstream gates unreliable. FcR blocking with excess non-specific IgG or dedicated blocking reagents (e.g., TruStain FcX, BD Fc Block) saturates these receptors before antibody staining so that only antigen-specific (Fab-mediated) binding occurs.